Source-grounded facts extracted from INTEST CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INTEST CORP shareholders approved Approval, on an advisory basis, of the compensation of our named executive officers at the 2026-06-17 meeting.
“Approval, on an advisory basis, of the compensation of our named executive officers: Votes For Votes Against Vote Abstained Broker Non-Votes 6,116,432 659,032 666,303 2,052,365”
INTEST CORP shareholders approved Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-17 meeting.
“Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal was approved by a vote of stockholders as follows: Votes For Votes Against Votes Abstained 9,394,702 97,639 1,791”
INTEST CORP shareholders approved Approval of Amendment No. 1 to the InTest Corporation 2023 Stock Incentive Plan at the 2026-06-17 meeting.
“Approval of Amendment No. 1 to the InTest Corporation 2023 Stock Incentive Plan. The proposal was approved by a vote of stockholders as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 6,760,213 283,087 398,467 2,052,365”
INTEST CORP shareholders approved Election of the five director nominees at the 2026-06-17 meeting.
“Each nominee for director was elected by a vote of the stockholders as follows: Nominee Votes For Vote Withheld Broker Non-Votes Steven J. Abrams, Esq. 6,357,910 1,083,857 2,052,365 Jeffrey A. Beck 7,301,009 140,758 2,052,365 Joseph W. Dews IV 7,297,086 144,681 2,052,365 Karl E. Johnsen 7,318,264 123,503 2,052,365 Richard Rogoff 7,333,191 108,576 2,052,365”
INTEST CORP reported first quarter of 2026 ended March 31, 2026 results: revenue $33.9 Million, net income $0.8 million, EPS $0.06. Guidance raised.
“InTest Reports Strong First Quarter 2026 Revenue of $33.9 Million EPS of $0.06 and Adjusted EPS (Non-GAAP) of $0.16”
INTEST CORP announced a restructuring with charges of $350,000 affecting Videology Imaging Corporation Netherlands facility (certain employees at that location).
“intends to fully vacate the Netherlands facility. As a result of this action, the Company expects to incur cash charges for severance and other one-time termination benefits of $350,000. In addition, the Company expects to incur cash charges for other costs related to the facility consolidation, including moving costs, costs associated with the termination of”
INTEST CORP entered into Purchase Agreement with Mauro Arigossi; Elettra S.S. valued at approximately €20 million (effective 2024-03-12).
“On March 12, 2024 inTEST Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) by and among inTEST Italy, Inc., a wholly owned subsidiary of the Company (“Buyer”), Mauro Arigossi (“Arigossi”), and Elettra S.S., a company incorporated under the Laws of Italy (“Elettra”, and together with Arigossi, each a “Seller” and collectively, the “Sellers”).”
INTEST CORP reported first quarter ended March 31, 2024 results: revenue $29.8 Million, EPS $0.05. Guidance reaffirmed.
“inTEST Reports $29.8 Million in Revenue for First Quarter 2024”
INTEST CORP amended credit facility with M&T Bank maturing May 2, 2031.
“the term loan and revolving credit facility maturity date is extended from September 19, 2027 to May 2, 2031.”
INTEST CORP reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 27, 2024, inTEST Corporation (the "Company") issued a press release regarding its financial results for the fourth quarter and year ended December 31, 2023.”
INTEST CORP completed an acquisition involving Mauro Arigossi and Elettra S.S. for approximately €20 million (closed 2024-03-12).
“all of the outstanding capital shares of Alfamation. Pursuant to the Purchase Agreement, the Buyer agreed to pay to the Sellers an aggregate base purchase price of approximately €20 million comprised of: (i) approximately €18 million in cash; and (ii) 187,432 shares of common stock of the Company, par value $0.01 (the “Shares”); and an additional approximately €542”
INTEST CORP entered into Lease Agreement with Elettra Real Estate S.r.l valued at €231,312 (effective 2024-03-12).
“In connection with the Purchase Agreement, Alfamation has entered into a lease agreement (the “Lease Agreement”) by and between Alfamation and Elettra Real Estate S.r.l , a limited liability company incorporated under the Laws of Italy (the “Landlord”).”
INTEST CORP entered into Purchase Agreement with Mauro Arigossi and Elettra S.S. valued at approximately €20 million (effective 2024-03-12).
“On March 12, 2024 inTEST Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) by and among inTEST Italy, Inc., a wholly owned subsidiary of the Company (“Buyer”), Mauro Arigossi (“Arigossi”), and Elettra S.S., a company incorporated under the Laws of Italy (“Elettra”, and together with Arigossi, each a “Seller” and collectively, the “Sellers”).”
INTEST CORP reported that prior financial statements should not be relied upon.
“should no longer be relied upon due to certain errors identified by the Company.”
INTEST CORP reported full year 2024 results: revenue in the range of $125 million to $130 million. Guidance initiated.
“Revenue for full year 2024 is expected to be in the range of $125 million to $130 million.”
INTEST CORP reported the first quarter of 2024 results: revenue in the range of $28 million to $30 million, EPS in the range of $0.08 to $0.13. Guidance initiated.
“Revenue for the first quarter of 2024 is expected to be in the range of $28 million to $30 million with gross margin of approximately 46%. First quarter 2024 earnings per diluted share is expected to be in the range of $0.08 to $0.13.”
INTEST CORP reported the fourth quarter ended December 31, 2023 results: revenue approximately $28.4 million, net income approximately $1.7 million, EPS $0.14 per diluted share.
“Fourth quarter 2023 revenue was approximately $28.4 million with net earnings of approximately $1.7 million, or $0.14 per diluted share.”
Scott Nolen departed as other at INTEST CORP.
“on January 9, 2024, inTEST Corporation (the “Company”) and Scott Nolen mutually agreed that Mr. Nolen’s employment with the Company would end effective immediately.”
Michael Goodrich was appointed as Division President, Process Technologies at INTEST CORP.
“The Company appointed Michael Goodrich to the position of Division President, Process Technologies effective January 15, 2023.”
Scott Nolen departed as Division President, Process Technologies at INTEST CORP.
“On January 9, 2024, inTEST Corporation (the “Company”) and Scott Nolen mutually agreed that Mr. Nolen’s employment with the Company would end effective immediately, and as a result he is no longer the Company’s Division President, Process Technologies.”
INTEST CORP entered into Lease Agreement with PERFECT PRESS SDN BHD valued at Ringgit Malaysia sixty-five thousand (RM65,000) monthly for three years; security deposit liquidated (effective 2024-04-01).
“On December 4,2023, inTEST SE ASIA SDN BHD (“inTEST Asia”), a newly-formed subsidiary of inTEST Corporation (the “Company”), entered into a lease agreement (the “Lease”) with PERFECT PRESS SDN BHD (the “Landlord”) for a 25,000 square foot facility located in Simpang Ampat, Pulau Pinang, Malaysia.”
INTEST CORP reported the third quarter ended September 30, 2023 results: revenue $32.7 million, net income $3.0 million, EPS $0.24.
“2 ex_589827.htm EXHIBIT 99.1 ex_589827.htm Exhibit 99.1 NEWS RELEASE 804 East Gate Drive, Suite 200 ● Mount Laurel, NJ 08054 for immediate release inTEST Reports Record $32.7 Million in Revenue for the 2023 Third Quarter with Earnings per Diluted Share up 4% to $0.24 Year-over-Year ● Continued execution of Five-Point Strategy delivers third quarter revenue of”
INTEST CORP reported the quarter ended June 30, 2023 results: revenue $32.6 Million, net income $2.8 million, EPS $0.24.
“inTEST Reports Record Revenue of $32.6 Million for the 2023 Second Quarter with Net Earnings Growth of 32% Year-over-Year”
INTEST CORP shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2023-06-21 meeting.
“4. Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The proposal was approved on an advisory basis by a vote of stockholders as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 4,659,886 874,233 255,617 2,769,979”
INTEST CORP shareholders approved Ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-21 meeting.
“3. Ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal was approved by a vote of stockholders as follows: Votes For Votes Against Votes Abstained 8,304,388 247,600 7,727”
INTEST CORP shareholders approved Approval of the inTEST Corporation 2023 Stock Incentive Plan. at the 2023-06-21 meeting.
“2. Approval of the inTEST Corporation 2023 Stock Incentive Plan. The proposal was approved by a vote of stockholders as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 5,623,590 145,629 20,517 2,769,979”
INTEST CORP shareholders approved Election of the five director nominees, with each director to serve until the next annual meeting of stockholders and until the election and qualification of such director’s successor. at the 2023-06-21 meeting.
“1. Election of the five director nominees, with each director to serve until the next annual meeting of stockholders and until the election and qualification of such director’s successor. Each nominee for director was elected by a vote of the stockholders as follows: Nominee Votes For Vote Withheld Broker Non-Votes Steven J. Abrams, Esq. 2,992,882 2,796,854 2,769,979 Jeffrey A. Beck 5,643,581 146,155 2,769,979 Joseph W. Dews IV 5,360,331 429,405 2,769,979 Richard N. Grant, Jr. 5,649,484 140,252 2,769,979 Gerald J. Maginnis 5,364,147 425,589 2,769,979”
INTEST CORP entered into Sales Agreement with Lake Street Capital Markets, LLC, as selling agent, and Northland Securities, Inc., d/b/a Northland Capital Markets, as co-agent valued at up to $20,000,000 (effective 2023-05-11).
“On May 11, 2023, inTEST Corporation (the "Company") entered into an At-the-Market Issuance Sales Agreement (the "Sales Agreement") with Lake Street Capital Markets, LLC, as selling agent (the “Agent”), and Northland Securities, Inc., d/b/a Northland Capital Markets, as co-agent, pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share ("Common Stock"), having an aggregate offering price of up to $20,000,000 (the "Shares"), from time to time through the Agent (the "Offering").”
INTEST CORP reported the first quarter ended March 31, 2023 results: revenue $31.9 million, net income $2.8 million, EPS $0.25 per diluted share. Guidance reaffirmed.
“● Achieved revenue of $31.9 million, up 32.5% versus the first quarter of 2022, and at upper end of guidance range ● Strong gross margin of 47.2% reflects favorable mix and impact of pricing actions taken last year ● Delivered net income of $2.8 million and earnings per diluted share of $0.25; adjusted earnings per diluted share (Non-GAAP) (1) was $0.29”
INTEST CORP reported the fourth quarter and year ended December 31, 2022 results: revenue $32.4 million, net income $3,244 thousand, EPS $0.30 per diluted share.
“Record fourth quarter revenue of $32.4 million increased 45% while record full year 2022 revenue of $116.8 million increased 38% versus the prior year”
INTEST CORP reported fourth quarter and full year 2022 for the period ended December 31, 2022 results: revenue approximately $32.4 million.
“and Acculogic (December 2021). Preliminary Unaudited Fourth Quarter and Year-End Performance and Business Highlights ● Fourth quarter revenue is expected to be approximately $32.4 million, a 44.9% increase compared to the fourth quarter of 2021 ● Full-year 2022 revenue is expected to be approximately $116.8 million, a 37.6% increase compared to full-year 2021 ●”
INTEST CORP entered into Lease with Apple Creek Properties Limited (effective 2022-11-30).
“On November 30, 2022, Acculogic Inc. (“Acculogic”), a subsidiary of inTEST Corporation, entered into a lease agreement (the “Lease”), with a term commencing on January 1, 2023 and ending on February 29, 2028, with Apple Creek Properties Limited (the “Landlord”) for approximately 16,437 square feet of office, warehouse and manufacturing space located in Markham, Ontario.”
INTEST CORP reported third quarter ended September 30, 2022 results: revenue $30.8 Million, net income $2.5 million, EPS $0.23.
“inTEST Reports Record Revenue of $30.8 Million and 16% Year-over-Year Growth in Net Income for Third Quarter 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.